Opinion
Video
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
At a median follow-up of 61.4 months, enzalutamide plus ADT continued to show an improvement in OS vs ADT alone.
Initial results from the phase 3 ARCHES trial (NCT02677896) showed an overall survival (OS) benefit with enzalutamide plus androgen deprivation therapy (ADT) vs ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC), which supported FDA approval of the combination in December 2019.
In a recent interview with Urology Times®, Andrew J. Armstrong, MD, MSc, shared key findings from the 5-year follow-up data of the trial, which will be shared during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Armstrong isa professor of medicine at Duke University in Durham, North Carolina.
Overall, data from the trial showed that at a median follow-up of 61.4 months, the combination of enzalutamide plus ADT continued to show an improvement in OS vs ADT alone (medians NR; HR 0.70; 95% CI, 0.58 to 0.85; P = .0003). At the time of data report, the median OS had not been reached in the treatment arm.
The OS benefit was consistent across all clinically relevant subgroups assessed.
Armstrong noted, “For some of the higher-risk groups, those who have what's called high volume disease, we show that, on average, patients are living 3 additional years longer than they are with the conventional standard of care androgen deprivation therapy.”
The importance of this survival benefit for patients cannot be overstated, according to Armstrong.
“For patients with low volume disease, we also see survival improvements, but the medians haven't been reached, meaning that most patients are making it well past 5 years,” he added. “We hope to someday be able to report on 10-year survival outcomes for these patients, which would be unprecedented when most patients didn't even make it that long in the past.”
REFERENCE
1. Armstrong A, Petrylak D, Shore N, et al. ARCHES: 5-year follow-up overall survival (OS) analysis of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol. 2025. doi: 10.1200/JCO.2025.43.16_suppl.5005. Abstract 5005
